Loading cancer entity…
Loading cancer entity…
Clinical trials
33 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (7)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02186847 | Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer | completed | Phase 2 | 170 | NRG OncologyOTHER | 3 | Jul 13, 2026 | clinicaltrials |
| NCT01642251 | Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 156 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2026 | clinicaltrials |
| NCT03845296 | Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | completed | Phase 2 | 64 | SWOG Cancer Research NetworkNETWORK | 1 | May 21, 2025 | clinicaltrials |
| NCT02264210 | Icotinib for Completed Resected IB NSCLC With EGFR Mutation(CORIN) | completed | Phase 2 | 128 | Sun Yat-sen UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT00950365 | Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 79 | Albert Einstein College of MedicineOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT01557959 | Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 45 | Wake Forest University Health SciencesOTHER | 1 | Jun 29, 2018 | clinicaltrials |
| NCT01294306 | MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2016 | clinicaltrials |
| NCT00368992 | S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2015 | clinicaltrials |
| NCT00040794 | Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | completed | Phase 2 | 144 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00118183 | Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00087412 | S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00021060 | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 842 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Jul 13, 2026source: clinicaltrials